Trial Profile
Randomized, Open-Label, 2-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary)
- Indications Breast cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 10 Oct 2019 Results of a cross-study analysis of total 7 studies(NCT01703481,NCT02218073,NCT02231489,EuDRACT-2015-001583-19,NCT02692677,NCT03066687and NCT03135106) published in the Journal of Clinical Pharmacology
- 22 Jun 2017 Status changed from recruiting to completed.
- 22 Mar 2017 Status changed from not yet recruiting to recruiting.